IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v7y2016i1d10.1038_ncomms11169.html
   My bibliography  Save this article

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer

Author

Listed:
  • Sherry Y. Wu

    (The University of Texas MD Anderson Cancer Center)

  • Rajesha Rupaimoole

    (The University of Texas MD Anderson Cancer Center)

  • Fangrong Shen

    (The University of Texas MD Anderson Cancer Center
    The First Affiliated Hospital of Soochow University)

  • Sunila Pradeep

    (The University of Texas MD Anderson Cancer Center)

  • Chad V. Pecot

    (The University of Texas MD Anderson Cancer Center
    The University of North Carolina)

  • Cristina Ivan

    (The University of Texas MD Anderson Cancer Center
    Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center)

  • Archana S. Nagaraja

    (The University of Texas MD Anderson Cancer Center)

  • Kshipra M. Gharpure

    (The University of Texas MD Anderson Cancer Center)

  • Elizabeth Pham

    (The University of Texas MD Anderson Cancer Center
    Biological Sciences Platform, Sunnybrook Research Institute)

  • Hiroto Hatakeyama

    (The University of Texas MD Anderson Cancer Center)

  • Michael H. McGuire

    (The University of Texas MD Anderson Cancer Center)

  • Monika Haemmerle

    (The University of Texas MD Anderson Cancer Center)

  • Viviana Vidal-Anaya

    (The University of Texas MD Anderson Cancer Center)

  • Courtney Olsen

    (The University of Texas MD Anderson Cancer Center)

  • Cristian Rodriguez-Aguayo

    (The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center)

  • Justyna Filant

    (The University of Texas MD Anderson Cancer Center)

  • Ehsan A. Ehsanipour

    (The University of Texas MD Anderson Cancer Center)

  • Shelley M. Herbrich

    (The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center)

  • Sourindra N. Maiti

    (The University of Texas MD Anderson Cancer Center)

  • Li Huang

    (The University of Texas MD Anderson Cancer Center)

  • Ji Hoon Kim

    (The University of Texas MD Anderson Cancer Center)

  • Xinna Zhang

    (Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center)

  • Hee-Dong Han

    (The University of Texas MD Anderson Cancer Center
    School of Medicine, Konkuk University)

  • Guillermo N. Armaiz-Pena

    (The University of Texas MD Anderson Cancer Center)

  • Elena G. Seviour

    (The University of Texas MD Anderson Cancer Center)

  • Sue Tucker

    (The University of Texas MD Anderson Cancer Center)

  • Min Zhang

    (University of Pittsburgh)

  • Da Yang

    (University of Pittsburgh)

  • Laurence J. N. Cooper

    (The University of Texas MD Anderson Cancer Center)

  • Rouba Ali-Fehmi

    (Wayne State University School of Medicine, Karmanos Cancer Institute)

  • Menashe Bar-Eli

    (The University of Texas MD Anderson Cancer Center)

  • Ju-Seog Lee

    (The University of Texas MD Anderson Cancer Center)

  • Prahlad T. Ram

    (The University of Texas MD Anderson Cancer Center)

  • Keith A. Baggerly

    (The University of Texas MD Anderson Cancer Center)

  • Gabriel Lopez-Berestein

    (The University of North Carolina
    The University of Texas MD Anderson Cancer Center)

  • Mien-Chie Hung

    (The University of Texas MD Anderson Cancer Center
    Center for Molecular Medicine, China Medical University)

  • Anil K. Sood

    (The University of Texas MD Anderson Cancer Center
    Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center)

Abstract

A deeper mechanistic understanding of tumour angiogenesis regulation is needed to improve current anti-angiogenic therapies. Here we present evidence from systems-based miRNA analyses of large-scale patient data sets along with in vitro and in vivo experiments that miR-192 is a key regulator of angiogenesis. The potent anti-angiogenic effect of miR-192 stems from its ability to globally downregulate angiogenic pathways in cancer cells through regulation of EGR1 and HOXB9. Low miR-192 expression in human tumours is predictive of poor clinical outcome in several cancer types. Using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes, we show that miR-192 delivery leads to inhibition of tumour angiogenesis in multiple ovarian and renal tumour models, resulting in tumour regression and growth inhibition. This anti-angiogenic and anti-tumour effect is more robust than that observed with an anti-VEGF antibody. Collectively, these data identify miR-192 as a central node in tumour angiogenesis and support the use of miR-192 in an anti-angiogenesis therapy.

Suggested Citation

  • Sherry Y. Wu & Rajesha Rupaimoole & Fangrong Shen & Sunila Pradeep & Chad V. Pecot & Cristina Ivan & Archana S. Nagaraja & Kshipra M. Gharpure & Elizabeth Pham & Hiroto Hatakeyama & Michael H. McGuire, 2016. "A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer," Nature Communications, Nature, vol. 7(1), pages 1-14, September.
    • Handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11169
    DOI: 10.1038/ncomms11169
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms11169
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms11169?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms11169. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.